Last update Aug. 19, 2022
Very Low Risk
It is a benzothiazepine-type calcium channel blocker and a class IV antiarrhythmic. It is used to treat hypertension and chronic stable angina. Oral or intravenous administration. It is also used topically in the treatment of anal fissure.
It is excreted in breast milk in a clinically non-significant amount. (Okada 85)
Two 6 months-old breastfed twins whose mother was treated with diltiazem did not get into health problems. (Lubbe 87)
Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Diltiazem does not have any influence on prolactin production. (Velardo 1992)
Several medical societies and expert authors consider the use of this medication possible during breastfeeding. (Hale, LactMed, Briggs 2015, Schaefer 2015, Serrano 2015, Rowe 2013). American Academy of Pediatrics: medication usually compatible with breastfeeding. (AAP 2001)
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug may be preferable, especially during the neonatal period and/or in case of premature infants.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM